



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/612,468	07/02/2003	Jingwu Z. Zang	057186.000003	5234

7590 05/04/2007
Attention: J. Wendy Davis, Ph.D.
BRACEWELL & PATTERSON, L.L.P.
P.O. Box 61389
Houston, TX 77208-1389

EXAMINER

JUEDES, AMY E

ART UNIT	PAPER NUMBER
----------	--------------

1644

MAIL DATE	DELIVERY MODE
-----------	---------------

05/04/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, DC 20231
www.uspto.gov

APPLICATION NO./CONTROL NO. 10/612,468	FILING DATE 07/02/03	FIRST NAMED INVENTOR/PATENT IN REEXAMINATION ZANG ET AL	ATTORNEY DOCKET NO.
---	-------------------------	--	---------------------

EXAMINER

Amy Juedes

ART UNIT PAPER

1644

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

A copy of the "Sequence Listing" in computer readable form has been submitted on 1/8/07. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

The addresses below are effective 5 June 2004. Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio
(<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. Mailed to:
Mail Stop Sequence
Commissioner for Patents
P.O. Box 22313-1450
Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service or other delivery service to:
U.S. Patent and Trademark Office
Mail Stop Sequence
Customer Window
Randolph Building
401 Dulaney Street
Alexandria, VA 22314

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Amy E. Juedes, Ph.D. whose telephone number is 571-272-4471. The examiner can normally be reached on 8am - 5pm, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Amy E. Juedes, Ph.D.
Patent Examiner
Technology Center 1600



4/30/07

**G.R. EWOLDT, PH.D.
PRIMARY EXAMINER**

Notice to Comply	Application No. 10/612,468	Applicant(s) ZANG ET AL.					
	Examiner Amy E. Juedes, Ph.D.	Art Unit 1644					
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES							
<p>Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).</p> <p>The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):</p>							
<p><input type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).</p> <p><input type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).</p> <p><input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).</p> <p><input checked="" type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."</p> <p><input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).</p> <p><input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).</p> <p><input type="checkbox"/> 7. Other:</p>							
<p>Applicant Must Provide:</p> <p><input checked="" type="checkbox"/> An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Listing".</p> <p><input checked="" type="checkbox"/> An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.</p> <p><input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).</p>							
<p>For questions regarding compliance to these requirements, please contact:</p> <p>For Rules Interpretation, call (571) 272-2510</p> <p>For CRF Submission Help, call (571) 272-2501/2583.</p> <p>PatentIn Software Program Support</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 40%;">Technical Assistance.....</td> <td style="width: 60%;">703-287-0200</td> </tr> <tr> <td>To Purchase PatentIn Software.....</td> <td>703-306-2600</td> </tr> </table> <p>PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY</p>				Technical Assistance.....	703-287-0200	To Purchase PatentIn Software.....	703-306-2600
Technical Assistance.....	703-287-0200						
To Purchase PatentIn Software.....	703-306-2600						

STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/612,468B
Source: 1Fwjb
Date Processed by STIC: 1/10/07

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<http://www.uspto.gov/ebc/efs/downloads/documents.htm>), EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/10/06



IFW16

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/612,468B

DATE: 01/10/2007
TIME: 09:43:35

Input Set : A:\D6622SEQ.txt
Output Set: N:\CRF4\0110200\J612468B.raw

3 <110> APPLICANT: Zhang, Jingwu Z.
4 Ho, Walter Kowk Keung
5 Zhang, Dongqing
6 Sun, Wei
8 <120> TITLE OF INVENTION: T Cell Receptor CDR3 Sequence and Methods for
9 Detecting and Treating Rheumatoid Arthritis
11 <130> FILE REFERENCE: D6622
13 <140> CURRENT APPLICATION NUMBER: US 10/612,468B
14 <141> CURRENT FILING DATE: 2003-07-02
16 <160> NUMBER OF SEQ ID NOS: 168

see pg 1-3

ERRORED SEQUENCES

416 <210> SEQ ID NO: 29
417 <211> LENGTH: 21
418 <212> TYPE: DNA
419 <213> ORGANISM: Artificial Sequence
421 <220> FEATURE:
422 <221> NAME/KEY: primer_bind
423 <223> OTHER INFORMATION: reverse primer specific for TCR BV11 used in real-time
424 PCR analysis *Insert a hard return after <400> 29*
426 <400> SEQUENCE: 29 atgtgagggc ctggcagact c 21

688 <210> SEQ ID NO: 50
689 <211> LENGTH: 23
E--> 690 *225 DNA* *212*
691 <213> ORGANISM: Artificial Sequence
693 <220> FEATURE:
694 <221> NAME/KEY: primer_bind
695 <223> OTHER INFORMATION: forward primer specific for TCR BV22 used in real-time
696 PCR analysis

698 <400> SEQUENCE: 50
699 cacagatggg acaggaagtg atc 23
727 <210> SEQ ID NO: 53
728 <211> LENGTH: 21
729 <212> TYPE: DNA
730 <213> ORGANISM: Artificial Sequence
732 <220> FEATURE: *221*
E--> 733 *211 primer_bind* *221*
734 <223> OTHER INFORMATION: reverse primer specific for TCR BV23 used in real-time
735 PCR analysis

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/612,468B

DATE: 01/10/2007
TIME: 09:43:35

Input Set : A:\D6622SEQ.txt
Output Set: N:\CRF4\01102007\J612468B.raw

737 <400> SEQUENCE: 53
738 cagctccaaag gagctcatgt t 21
740 <210> SEQ ID NO: 54
741 <211> LENGTH: 24
742 <212> TYPE: DNA
743 <213> ORGANISM: Artificial Sequence
745 <220> FEATURE:
746 <221> NAME/KEY: primer_bind
747 <223> OTHER INFORMATION: forward primer specific for TCR BV24 used in real-time PCR analysis *Insert a hard return*
750 <400> SEQUENCE: 54 ccaagataacc aggttaccca gttt 24

1271 <210> SEQ ID NO: 93
1272 <211> LENGTH: 20
1273 <212> TYPE: PRT
1274 <213> ORGANISM: Homo sapiens
1276 <220> FEATURE:
1277 <221> NAME/KEY: Domain
1278 <223> OTHER INFORMATION: CDR3 amino acid sequence of BV16 clonotype derived from ST specimen of RA patient
1281 <400> SEQUENCE: 93
1282 Tyr Phe Cys Ala Ser Ser Gln Ala Asp Gly Thr His Tyr Glu Gln
1283 5 10 15
1284 Phe Phe Gly Pro Gly
E--> 1285 20 *misaligned amino acid number*
1287 <210> SEQ ID NO: 94
1288 <211> LENGTH: 60 <212>
E--> 1289 <213> DNA
1290 <213> ORGANISM: Artificial Sequence
1292 <220> FEATURE:
1293 <221> NAME/KEY: CDS
1294 <223> OTHER INFORMATION: CDR3 nucleic acid sequence of BV16 clonotype derived from ST specimen of RA patients

1298 <400> SEQUENCE: 94
1299 tatttctgtg ccagcagcca agctgacggg acccattacg agcagtactt 50
1300 cggggccgggc 60
1968 <210> SEQ ID NO: 140
1969 <211> LENGTH: 57 <212>
E--> 1970 <213> DNA
1971 <213> ORGANISM: Artificial Sequence
1973 <220> FEATURE:
1974 <221> NAME/KEY: CDS
1975 <223> OTHER INFORMATION: CDR3 nucleic acid sequence of BV14 clonotype derived from ST specimen of RA patients

1978 <400> SEQUENCE: 140
1979 tacttctgtg ccagcagttt atcttcgaca gggagggagc agtacttcgg gccgggc 57
2371 <210> SEQ ID NO: 168

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/612,468B

DATE: 01/10/2007
TIME: 09:43:35

Input Set : A:\D6622SEQ.txt
Output Set: N:\CRF4\01102007\J612468B.raw

2372 <211> LENGTH: 54
2373 <212> TYPE: DNA
2374 <213> ORGANISM: Artificial Sequence
2376 <220> FEATURE:
2377 <221> NAME/KEY: CDS
2378 <223> OTHER INFORMATION: CDR3 nucleic acid sequence of BV14 clonotype derived
2379 from ST specimen of RA patients
2381 <400> SEQUENCE: 168
2382 tacttctgtg ccagcagttc cctcgctact gctgaagctt tctttggaca aggc 54
E--> 2383 ?? *(circle)*
E--> 2385 ?? *(circle)*
E--> 2387 ?? *(circle)* delete
E--> 2389 ??

VERIFICATION SUMMARY
PATENT APPLICATION: US/10/612,468B

DATE: 01/10/2007
TIME: 09:43:36

Input Set : A:\D6622SEQ.txt
Output Set: N:\CRF4\01102007\J612468B.raw

L:426 M:301 E: (44) No Sequence Data was Shown, SEQ ID:29
L:426 M:252 E: No. of Seq. differs, <211> LENGTH:Input:21 Found:0 SEQ:29
L:690 M:250 E: Invalid Numeric Identifier, INVALID IDENTIFIER
L:698 M:282 E: Numeric Field Identifier Missing, <212> is required.
L:733 M:250 E: Invalid Numeric Identifier, INVALID IDENTIFIER
L:750 M:301 E: (44) No Sequence Data was Shown, SEQ ID:54
L:750 M:252 E: No. of Seq. differs, <211> LENGTH:Input:24 Found:0 SEQ:54
L:1285 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:93
L:1289 M:250 E: Invalid Numeric Identifier, INVALID IDENTIFIER
L:1298 M:282 E: Numeric Field Identifier Missing, <212> is required.
L:1970 M:250 E: Invalid Numeric Identifier, INVALID IDENTIFIER
L:1978 M:282 E: Numeric Field Identifier Missing, <212> is required.
L:2383 M:334 E: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1
L:2385 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:168
L:2385 M:334 E: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1
L:2387 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:168
L:2387 M:334 E: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1
L:2389 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:168
L:2399 M:334 E: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1